Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) – Pipeline Review, H2 2017’, provides in depth analysis on Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Cardiovascular, Oncology and Women's Health under development targeting Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.

Scope

The report provides a snapshot of the global therapeutic landscape for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)

The report reviews Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics and enlists all their major and minor projects

The report assesses Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC 3.4.11.7) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

APAvadis Biotechnologies Srl

Quantum Genomics SA

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Overview 6

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Therapeutics Development 7

Products under Development by Stage of Development 7

Products under Development by Therapy Area 8

Products under Development by Indication 9

Products under Development by Companies 10

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Therapeutics Assessment 12

Assessment by Mechanism of Action 12

Assessment by Route of Administration 13

Assessment by Molecule Type 14

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Companies Involved in Therapeutics Development 16

APAvadis Biotechnologies Srl 16

Quantum Genomics SA 17

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Drug Profiles 18

Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 18

Product Description 18

Mechanism Of Action 18

R&D Progress 18

QGC-001 - Drug Profile 19

Product Description 19

Mechanism Of Action 19

R&D Progress 19

QGC-006 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

QGC-011 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

QGC-101 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

Glutamyl Aminopeptidase (EAP or Aminopeptidase A or Differentiation Antigen gp160 or CD249 or ENPEP or EC

3.4.11.7) - Product Development Milestones 26

Featured News & Press Releases 26

Sep 05, 2017: Quantum Genomics Receives FDA Clearance of IND Application for QGC001 26

Jun 28, 2017: Quantum Genomics announces the design of its next Phase II trial in arterial hypertension, NEW-HOPE 26

Jun 19, 2017: Quantum Genomics details positive results from its Phase IIa trial of QGC001 for the treatment of arterial hypertension 27

May 09, 2017: Quantum Genomics will organize a teleconference on June 19, 2017, to comment on phase IIa data in high blood pressure 29

Mar 14, 2017: Quantum Genomics announces positive data from new preclinical studies with QGC001 29

Feb 02, 2017: Quantum Genomics granted key European patent for QGC011 combination therapy program 30

Sep 29, 2016: Quantum Genomics reports positive top-line results from Phase IIa trial of QGC001 in hypertension 30

Sep 12, 2016: Quantum Genomics to announce Phase IIa clinical trial results for high blood pressure on September 29, 2016 31

May 17, 2016: Quantum Genomics granted two new U.S. patents covering lead product QGC001 31

Feb 03, 2016: Quantum Genomics Expands U.S. Presence to Advance Its Development Programs for Cardiovascular Diseases 32

Oct 06, 2015: Positive opinion from Monitoring Board to continue protocol as planned, for Phase IIa clinical trial under way for high blood pressure 33

Sep 22, 2015: Quantum Genomics to meet investors at the European Large & Midcap Event, October 7 & 8, 2015 34

Mar 03, 2015: First patients recruited for Phase IIa trial of drug candidate QGC001 34

Jan 12, 2015: Quantum Genomics at J.P. Morgan 34th annual healthcare conference 35

Dec 11, 2014: Catherine Llorens-Cortes receives the 2014 Galien France pharmaceutical research award for her work on the key role of angiotensin III at brain level in the control of blood pressure 35

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Indication, H2 2017 9

Number of Products under Development by Companies, H2 2017 10

Products under Development by Companies, H2 2017 11

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Stage and Route of Administration, H2 2017 13

Number of Products by Stage and Molecule Type, H2 2017 15

Pipeline by APAvadis Biotechnologies Srl, H2 2017 16

Pipeline by Quantum Genomics SA, H2 2017 17

List of Figures

List of Figures

Number of Products under Development by Stage of Development, H2 2017 7

Number of Products under Development by Therapy Areas, H2 2017 8

Number of Products under Development by Top 10 Indications, H2 2017 9

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Molecule Types, H2 2017 14

Number of Products by Stage and Molecule Types, H2 2017 14

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports